Showing 101 - 120 results of 133 for search 'Zhao Baofang~', query time: 2.46s Refine Results
  1. 101
  2. 102
  3. 103
  4. 104
  5. 105
  6. 106
  7. 107
  8. 108
  9. 109
  10. 110
  11. 111
  12. 112
  13. 113
  14. 114
  15. 115
  16. 116
  17. 117

    Comparative Efficacy of Esketamine vs Sufentanil with Propofol for Sedation in EUS: A Randomized, Controlled Study by Liu C, Wang Y, Yin Y, Wang P, Ji X, Sun J, Zhao S, Jia Y, Liu S, Zhou Z

    Published 2025-01-01
    “…Cuicui Liu,1,* Yanting Wang,1,* Yanwei Yin,2 Pei Wang,1 Xiangyu Ji,1 Jian Sun,1 Shuo Zhao,1 Yanfang Jia,1 Shanling Liu,1 Zangong Zhou1 1Daytime Anesthesiology Department, the Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People’s Republic of China; 2Pain Department, the Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People’s Republic of China*These authors contributed equally to this workCorrespondence: Zangong Zhou, Daytime Anesthesiology Department, the Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Shinan District, Qingdao, Shandong Province, 266000, People’s Republic of China, Tel +86 532-82912511, Email zhouzangong@qdu.edu.cnPurpose: This randomized, controlled trial aimed to assess the sedative effects of esketamine and sufentanil combined with propofol during EUS.Patients and Methods: Three hundred and forty patients undergone EUS were randomly divided into two groups to receive esketamine 0.25 mg/kg combined with propofol (esketamine group) or sufentanil 0.1 μg/kg combined with propofol (sufentanil group). …”
    Get full text
    Article
  18. 118

    Non-Luminal Disease Score for Everolimus in Patients with Hormone Receptor‑positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Mult... by Tan Y, Jiang H, Tian X, Ma F, Wang J, Zhang P, Xu B, Fan Y, Zhao W

    Published 2025-01-01
    “…Yujing Tan,1,* Hanfang Jiang,2,* Xinzhu Tian,1,* Fei Ma,1 Jiayu Wang,1 Pin Zhang,1 Binghe Xu,1 Ying Fan,1 Weihong Zhao3 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, People’s Republic of China; 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, People’s Republic of China; 3Department of Medical Oncology, Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ying Fan; Weihong Zhao, Email fanying@cicams.ac.cn; zhaowh0818@163.comPurpose: This study aims to explore the role of the non-luminal disease score (NOLUS) for everolimus in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC).Methods: NOLUS has previously been established as an algorithm: NOLUS (0– 100) = − 0.45 × ER(%) − 0.28 × PR(%) + 0.27 × Ki67(%) + 73. …”
    Get full text
    Article
  19. 119
  20. 120